LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Kodu・Aktsiate loetelu・Amgen Inc

Amgen Inc

Suletud

Sektor Tervishoid

319.72 1.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

313.27

Max

320.98

Põhinäitajad
By Trading Economics
Sissetulek	859M 746M
Müük	940M 8.4B
P/E Sektori keskmine	44.64 112.16
Aktsiakasum	4.97
Kasumimarginaal	8.892
Töötajad	26,700
EBITDA	847M 3B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+7.66 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024
Järgmine dividendimakse kuupäev	6. dets 2024
Järgmine aktsia dividendi kuupäev (ex-date)	14. nov 2024

Turustatistika
By TradingEconomics
Turukapital	4.1B 175B
Eelmine avamishind	318.67
Eelmine sulgemishind	319.72

Uudiste sentiment

By Acuity

47%

53%

144 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

315.92 / 322.41 Toetus ja vastupanu

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2024, 21:00 UTC

Tulu

Amgen 2Q Revenue Jumps, Profit Narrows on Higher Expenses

2. mai 2024, 20:42 UTC

Tulu

Amgen Posts Higher 1Q Revenue, Swings to Loss

25. sept 2024, 16:19 UTC

Peamised uudised

Dow Falls, Nasdaq Rises, Chinese Shares Rally -- WSJ

20. sept 2024, 13:55 UTC

Peamised uudised

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

10. sept 2024, 20:38 UTC

Omandamised, ülevõtmised, äriostud

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

10. sept 2024, 14:42 UTC

Omandamised, ülevõtmised, äriostud

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

3. sept 2024, 04:00 UTC

Peamised uudised

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

7. aug 2024, 14:22 UTC

Peamised uudised

Tulu

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7. aug 2024, 09:07 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7. aug 2024, 08:55 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

6. aug 2024, 20:20 UTC

Tulu

Amgen Sees FY24 Share Repurchases Not Exceeding $500 M >AMGN

6. aug 2024, 20:20 UTC

Tulu

Amgen Sees FY24 Capital Expenditures About $1.3 B >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q EPS $1.38 >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Adj EPS $4.97 >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Worldwide Neulasta Sales $105M >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Worldwide Prolia Sales $1.17B >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen Sees FY Adj EPS $19.10-Adj EPS $20.10 >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Net $746M >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Worldwide XGEVA Sales $562M >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen Sees FY EPS $6.57-EPS $7.62 >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Rev $8.4B >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen 2Q Worldwide Enbrel Sales $909M >AMGN

6. aug 2024, 20:01 UTC

Tulu

Amgen Sees FY Rev $32.8B-$33.8B >AMGN

6. aug 2024, 08:45 UTC

Peamised uudised

Tulu

These Stocks Are Moving the Most Today: Palantir, Nvidia, Apple, Lumen, Lucid, Caterpillar, and More -- Barrons.com

19. juuli 2024, 11:00 UTC

Peamised uudised

Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ

19. juuni 2024, 05:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

3. mai 2024, 14:43 UTC

Kuumad aktsiad

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3. mai 2024, 11:43 UTC

Market Talk

Tulu

Amgen's Weight-Loss Drug Prospects Win New Bull -- Market Talk

3. mai 2024, 08:45 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Apple, Amgen, Block -- WSJ

3. mai 2024, 08:28 UTC

Tulu

These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

7.66% tõus

12 kuu keskmine prognoos

Keskmine 341 USD 7.66%

Kõrge 405 USD

Madal 215 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Amgen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

315.92 / 322.41Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Sentiment

By Acuity

144 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.